+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Asthmatics and COPD Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth

  • ID: 5440757
  • Report
  • September 2021
  • Region: Global
  • 344 Pages
  • The Business Research Company

FEATURED COMPANIES

  • AstraZeneca plc
  • Boehringer-Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG

Anti-Asthmatics and COPD Drugs Global Market Opportunities and Strategies To 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global anti-asthmatics and COPD drugs market as it emerges from the COVID 19 shut down.







Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Description:

Where is the largest and fastest growing market for anti-asthmatics and COPD drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-asthmatics and COPD drugs market global report from the publisher answers all these questions and many more.


The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider anti-asthmatics and COPD drugs market, and compares it with other markets.



The report covers the following chapters


  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by drug class, segmentation by end-user, segmentation by distribution channel, segmentation by therapy, segmentation by route of administration, segmentation by age group, segmentation by prescription and segmentation by drug type.
  • Market Characteristics - The market characteristics section of the report defines and explains the anti-asthmatics and COPD drugs market. This chapter also defines and describes products and related services covered in the report.
  • Supply Chain -The supply chain section of the report defines and explains the key players in the anti-asthmatics and COPD drugs industry supply chain.
  • Product Analysis -The product analysis section of the report describes the leading products in the market along with key features and differentiators for those products.
  • Top 10 Leading Drugs Sales -The section describes list of top 10 drugs and their sales in the anti-asthmatics and COPD drug market in 2020. It briefs on the drug chemical composition, drug class and the manufacturers involved in manufacturing and selling of these leading drugs in the anti-asthmatics and COPD drugs market.
  • Patent Analysis Of Leading Drugs -The section briefs on the patent analysis of the leading drugs in the anti-asthmatics and COPD drugs market, by focusing on the leading drugs’ patent expiry and emergence of the generic drugs in the market.
  • Customer Information - This chapter covers recent customers’ trends/preferences in the global anti-asthmatics and COPD drugs market.
  • Impact Of COVID-19 - This section describes the impact of COVID-19 on the anti-asthmatics and COPD drugs market.
  • Regulatory Landscape - This section describes the regulatory bodies and regulations on the anti-asthmatics and COPD drugs market.
  • Trends and Strategies - This chapter describes the major trends shaping the global anti-asthmatics and COPD drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Asthma and COPD Prevalence Overview-This section describes about asthma and COPD and their prevalence in the major countries.
  • Global Market Size and Growth - This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
  • Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
  • Global Macro Comparison - The global anti-asthmatics and COPD drugs market comparison with macro-economic factors gives the anti-asthmatics and COPD drugs market size, percentage of GDP, and average anti-asthmatics and COPD drugs market expenditure.
  • Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global anti-asthmatics and COPD drugs market, estimated market shares and company profiles for the leading players.
  • Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Background - This section describes the respiratory diseases drugs market of which the anti-asthmatics and COPD drugs market is a segment. This chapter includes the respiratory diseases drugs market 2015-23 values, and regional analyses for the respiratory diseases drugs market.
  • Market Opportunities and Strategies- This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for anti-asthmatics and COPD drugs providers in terms of product offerings, geographic expansion, price offerings, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope


Markets Covered:



  1. By Drug Class: Combination Drugs; Bronchodilators; Monoclonal Antibodies; Anti-Inflammatory Drugs
  2. By End User: Asthma Patients; COPD Patients
  3. By Distribution Channel: General Pharmacies; Hospital Pharmacies; Online Retailers
  4. By Age Group: Below 5 Years; 5 To 14 Years; 15-60 Years; Above 60 Years
  5. By Therapy: Preventive; Curative
  6. By Route Of Administration: Inhaled; Intravenous; Subcutaneous; Oral
  7. By Prescription: Prescription; OTC
  8. By Drug Type: Branded; Generics

Companies Mentioned:

GlaxoSmithKline plc.; AstraZeneca plc.; Boehringer-Ingelheim GmbH; F. Hoffmann-La Roche Ltd; Novartis AG


Metrics Covered:

Number of Enterprises; Number of Employees; Per Capita Expenditure


Countries:

China; India; Japan; Australia; Indonesia; South Korea; USA; Brazil; UK; Germany; France; Russia


Regions:

Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa


Time series:

Five years historic and ten years forecast.


Data:

Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; Anti-Asthmatics and COPD Drugs indicators comparison.


Data segmentations:

Country and regional historic and forecast data; market share of competitors; market segments.


Sourcing and Referencing:

Data and analysis throughout the report is sourced using end notes.

Frequently Asked Questions about the Global Anti-Asthmatics and COPD Drugs Market

What is the estimated value of the Global Anti-Asthmatics and COPD Drugs Market?

The Global Anti-Asthmatics and COPD Drugs Market was estimated to be valued at $75376.4 Million in 2020.

What is the growth rate of the Global Anti-Asthmatics and COPD Drugs Market?

The growth rate of the Global Anti-Asthmatics and COPD Drugs Market is 4.3%, with an estimated value of $114413.5 Million by 2030.

What is the forecasted size of the Global Anti-Asthmatics and COPD Drugs Market?

The Global Anti-Asthmatics and COPD Drugs Market is estimated to be worth $114413.5 Million by 2030.

Who are the key companies in the Global Anti-Asthmatics and COPD Drugs Market?

Key companies in the Global Anti-Asthmatics and COPD Drugs Market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer, Ingelheim GmbH, F. Hoffmann and Novartis AG.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca plc
  • Boehringer-Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG

1. Anti-Asthmatics and COPD Drugs Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
6.1. Segmentation By Geography
6.2. Segmentation By Drug Class
6.3. Segmentation By End User
6.4. Segmentation By Distribution Channel
6.5. Segmentation By Therapy
6.6. Segmentation By Route Of Administration
6.7. Segmentation By Age Group
6.8. Segmentation By Prescription
6.9. Segmentation By Drug Type
7. Anti-Asthmatics and COPD Drugs Market Characteristics
7.1. Market Segmentation By Drug Class
7.1.1. Bronchodilators
7.1.2. Anti-Inflammatory Drugs
7.1.3. Monoclonal Antibodies
7.1.4. Combination Drugs
7.2. Market Segmentation By End User
7.2.1. Asthma Patients
7.2.2. COPD Patients
7.3. Market Segmentation By Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. General Pharmacies
7.3.3. Online Retailers
7.4. Market Segmentation By Therapy
7.4.1. Preventive
7.4.2. Curative
7.5. Market Segmentation By Route Of Administration
7.5.1. Oral
7.5.2. Inhaled
7.5.3. Intravenous
7.5.4. Subcutaneous
7.6. Market Segmentation By Age Group
7.6.1. Below 5
7.6.2. 5-14
7.6.3. 15-60
7.6.4. Above 60
7.7. Market Segmentation By Prescription
7.7.1. Prescription
7.7.2. Over The Counter (OTC)
7.8. Market Segmentation By Drug Type
7.8.1. Branded
7.8.2. Generic
8. Anti-Asthmatics and COPD Drugs Market, Supply Chain Analysis
8.1. Raw Material and Equipment Procurement
8.2. Manufacturing, Processing and Packaging
8.3. Distribution
8.4. Physicians
8.5. End users
9. Anti-Asthmatics and COPD Drugs Market, Product Pipeline Analysis
10. Anti-Asthmatics and COPD Drugs Market, Top 10 Leading Drugs Sales
10.1. Ellipta
10.2. Symbicort
10.3. Spiriva
10.4. Advair
10.5. Nucala
10.6. Xolair
10.7. Ventolin
10.8. Pulmicort
10.9. Fasenra
10.10. Flovent
11. Anti-Asthmatics and COPD Drugs Market, Patent Analysis Of Leading Drugs
11.1. Background
11.2. Innovators
12. Anti-Asthmatics and COPD Drugs Market, Customer Information
12.1. Challenges Faced By Asthma Patients During COVID-19 Pandemic
12.2. COVID-19 Impact On Asthma-Related Quality Of Life
12.3. Asthma Patients Attitude Towards Cannabis
12.4. Availability and Affordability Of Asthma and COPD Drugs In Nigeria
12.5. Majority Of Australian COPD Patients Are Physically Inactive and Obese
12.6. Britons Experience Inadequate Treatment Of COPD
12.7. COPD Patients Are More Likely To Be Current Daily Smokers Or Ex-Smokers
12.8. Uncontrolled Asthma Patients Face Recurring Symptoms and Doctor Visits
12.9. Uncontrolled Asthma Patients Struggle With Mobility Issues
13. Impact of COVID-19 On The Anti-Asthmatics and COPD Drugs Market
13.1. Consumer Perception
13.2. COVID-19 Impact On Asthma Patients
13.3. Anti-Asthmatic and COPD Drugs Used In COVID-19 Treatment
13.4. New Drugs Developments and Pilot Studies
13.5. Future Outlook
14. Anti-Asthmatics and COPD Drugs Market Regulatory Landscape
14.1. India
14.2. China
14.3. Japan
14.4. Australia
14.5. South Korea
14.6. Indonesia
14.7. USA
14.8. Canada
14.9. Mexico
14.10. UK
14.11. Germany
14.12. France
14.13. Russia
14.14. Brazil
15. Anti-Asthmatics and COPD Drugs Market Trends and Strategies
15.1. Use Of Probiotics To Treat Asthma
15.2. Anti-IL-5 Treatment For Patients With Severe Asthma
15.3. New Product Launches
15.4. Bioelectric Medicine For Asthma Patients
15.5. Collaborations In The Anti-Asthmatics and COPD Drugs Market
15.6. Increasing Demand For Personalized Medicines
15.7. Demand For Aerosol Respiratory Drugs
15.8. Use Of Biomarker For Precision Medicine
15.9. Rise Of Generic Respiratory Drugs
15.10. Combination Drug Therapy To Treat COPD
15.11. New Biologic Therapy Medicines To Treat Severe Asthma
16. Asthma and COPD Prevalence Overview
16.1. Asthma
16.2. COPD
17. Global Anti-Asthmatics and COPD Drugs Market Size and Growth
17.1. Market Size
17.2. Historic Market Growth, 2015 - 2020, Value ($ Million)
17.2.1. Drivers Of The Market 2015 - 2020
17.2.2. Restraints On The Market 2015 - 2020
17.3. Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
17.3.1. Drivers Of The Market 2020 - 2025
17.3.2. Restraints On The Market 2020 - 2025
18. Anti-Asthmatics and COPD Drugs Market, Regional and Country Analysis
18.1. Global Anti-Asthmatics and COPD Drugs Market, By Region, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
18.2. Global Anti-Asthmatics and COPD Drugs Market, By Country, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
19. Global Anti-Asthmatics and COPD Drugs Market Segmentation
19.1. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
19.1.1. Combination Drugs
19.1.2. Bronchodilators
19.1.3. Monoclonal Antibodies
19.1.4. Anti-Inflammatory Drugs
19.2. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
19.2.1. Asthma Patients
19.2.2. COPD Patients
19.3. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
19.4. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By Therapy, 2020, Value ($ Million)
19.4.1. Preventive
19.4.2. Curative
19.5. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By Route Of Administration, 2020, Value ($ Million)
19.6. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By Patients’ Age Group, 2020, Value ($ Million)
19.6.1. 15-69 Years
19.7. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By Type Of Prescription, 2020, Value ($ Million)
19.7.1. Prescription
19.7.2. OTC
19.8. Global Anti-Asthmatics and COPD Drugs Market, Segmentation By Type of Drug, 2020, Value ($ Million)
19.8.1. Branded
19.8.2. Generics
20. Asia-Pacific Anti-Asthmatics and COPD Drugs Market
20.1. Asia-Pacific Anti-Asthmatics and COPD Drugs Market Overview
20.1.1. Region Information
20.1.2. Market Information
20.1.3. COVID-19 Impact
20.1.4. Background Information
20.1.5. Government Initiatives
20.1.6. New Drug Trials and Approvals
20.1.7. Regulations
20.1.8. Regulatory Bodies
20.1.9. Major Associations
20.1.10. Taxes Levied
20.1.11. Corporate Tax Structure
20.1.12. Investments
20.1.13. Major Companies
20.2. Asia-Pacific Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.3. Asia-Pacific Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
20.4. Asia-Pacific Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.5. Asia-Pacific Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.6. Asia-Pacific Anti-Asthmatics and COPD Drugs Market: Country Analysis
20.7. China Anti-Asthmatics and COPD Drugs Market
20.8. China Anti-Asthmatics and COPD Drugs Market Overview
20.8.1. Country Information
20.8.2. Market Information
20.8.3. COVID-19 Impact
20.8.4. Background Information
20.8.5. Government Initiatives
20.8.6. New Drug Trials and Approvals
20.8.7. Regulations
20.8.8. Regulatory Bodies
20.8.9. Major Associations
20.8.10. Taxes Levied
20.8.11. Corporate Tax Structure
20.8.12. Investments
20.8.13. Major Companies
20.9. China Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.10. China Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
20.11. China Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.12. China Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.13. India Anti-Asthmatics and COPD Drugs Market
20.14. India Anti-Asthmatics and COPD Drugs Market Overview
20.14.1. Country Information
20.14.2. Market Information
20.14.3. COVID-19 Impact
20.14.4. Background Information
20.14.5. Government Initiatives
20.14.6. New Drug Trials and Approvals
20.14.7. Major Associations
20.14.8. Regulations
20.14.9. Regulatory Bodies
20.14.10. Taxes Levied
20.14.11. Corporate Tax Structure
20.14.12. Investments
20.14.13. Major Companies
20.15. India Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.16. India Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
20.17. India Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.18. India Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.19. Japan Anti-Asthmatics and COPD Drugs Market
20.20. Japan Anti-Asthmatics and COPD Drugs Market Overview
20.20.1. Country Information
20.20.2. Market Information
20.20.3. COVID-19 Impact
20.20.4. Background Information
20.20.5. Government Initiatives
20.20.6. New Drug Trials and Approvals
20.20.7. Regulations
20.20.8. Regulatory Bodies
20.20.9. Major Associations
20.20.10. Taxes Levied
20.20.11. Corporate Tax Structure
20.20.12. Investments
20.20.13. Major Companies
20.21. Japan Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.22. Japan Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
20.23. Japan Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.24. Japan Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.25. Australia Anti-Asthmatics and COPD Drugs Market
20.26. Australia Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.27. Australia Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
20.28. Australia Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.29. Australia Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.30. Indonesia Anti-Asthmatics and COPD Drugs Market
20.31. Indonesia Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.32. Indonesia Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
20.33. Indonesia Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.34. Indonesia Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.35. South Korea Anti-Asthmatics and COPD Drugs Market
20.36. South Korea Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.37. South Korea Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
20.38. South Korea Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
20.39. South Korea Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users , Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21. Western Europe Anti-Asthmatics and COPD Drugs Market
21.1. Western Europe Anti-Asthmatics and COPD Drugs Market Overview
21.1.1. Region Information
21.1.2. Market Information
21.1.3. COVID-19 Impact
21.1.4. Background Information
21.1.5. Government Initiatives
21.1.6. New Drug Trials and Approvals
21.1.7. Regulations
21.1.8. Regulatory Bodies
21.1.9. Major Associations
21.1.10. Taxes Levied
21.1.11. Corporate Tax Structure
21.1.12. Major Companies
21.2. Western Europe Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
21.3. Western Europe Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
21.4. Western Europe Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21.5. Western Europe Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21.6. Western Europe Anti-Asthmatics and COPD Drugs Market: Country Analysis
21.7. UK Anti-Asthmatics and COPD Drugs Market
21.8. UK Anti-Asthmatics and COPD Drugs Market Overview
21.8.1. Country Information
21.8.2. Market Information
21.8.3. COVID-19 Impact
21.8.4. Background Information
21.8.5. Government Initiatives
21.8.6. New Drug Trials and Approvals
21.8.7. Regulations
21.8.8. Regulatory Bodies
21.8.9. Major Associations
21.8.10. Taxes Levied
21.8.11. Corporate Tax Structure
21.8.12. Major Companies
21.9. UK Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
21.10. UK Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
21.11. UK Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21.12. UK Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21.13. Germany Anti-Asthmatics and COPD Drugs Market
21.14. Germany Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
21.15. Germany Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
21.16. Germany Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21.17. Germany Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21.18. France Anti-Asthmatics and COPD Drugs Market
21.19. France Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
21.20. France Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
21.21. France Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
21.22. France Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
22. Eastern Europe Anti-Asthmatics and COPD Drugs Market
22.1. Eastern Europe Anti-Asthmatics and COPD Drugs Market Overview
22.1.1. Region Information
22.1.2. Market Information
22.1.3. COVID-19 Impact
22.1.4. Background Information
22.1.5. Government Initiatives
22.1.6. New Drug Trials and Approvals
22.1.7. Regulations
22.1.8. Regulatory Bodies
22.1.9. Major Associations
22.1.10. Taxes Levied
22.1.11. Corporate Tax Structure
22.1.12. Investments
22.1.13. Major Companies
22.2. Eastern Europe Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
22.3. Eastern Europe Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
22.4. Eastern Europe Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
22.5. Eastern Europe Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
22.6. Eastern Europe Anti-Asthmatics and COPD Drugs Market: Country Analysis
22.7. Russia Anti-Asthmatics and COPD Drugs Market
22.8. Russia Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
22.9. Russia Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
22.10. Russia Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
22.11. Russia Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
23. North America Anti-Asthmatics and COPD Drugs Market
23.1. North America Anti-Asthmatics and COPD Drugs Market Overview
23.1.1. Region Information
23.1.2. Market Information
23.1.3. COVID-19 Impact
23.1.4. Background Information
23.1.5. Government Initiatives
23.1.6. New Drug Trials and Approvals
23.1.7. Regulations
23.1.8. Regulatory Bodies
23.1.9. Major Associations
23.1.10. Taxes Levied
23.1.11. Corporate Tax Structure
23.1.12. Investments
23.1.13. Major Companies
23.2. North America Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
23.3. North America Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
23.4. North America Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
23.5. North America Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
23.6. North America Anti-Asthmatics and COPD Drugs Market: Country Analysis
23.7. USA Anti-Asthmatics and COPD Drugs Market
23.8. USA Anti-Asthmatics and COPD Drugs Market Overview
23.8.1. Country Information
23.8.2. Market Information
23.8.3. COVID-19 Impact
23.8.4. Background Information
23.8.5. Government Initiatives
23.8.6. New Drug Trials and Approvals
23.8.7. Regulations
23.8.8. Regulatory Bodies
23.8.9. Major Associations
23.8.10. Taxes Levied
23.8.11. Corporate Tax Structure
23.8.12. Investments
23.8.13. Major Companies
23.9. USA Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
23.10. USA Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
23.11. USA Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
23.12. USA Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
24. South America Anti-Asthmatics and COPD Drugs Market
24.1. South America Anti-Asthmatics and COPD Drugs Market Overview
24.1.1. Region Information
24.1.2. Market Information
24.1.3. COVID-19 Impact
24.1.4. Background Information
24.1.5. Government Initiatives
24.1.6. New Drug Trials and Approvals
24.1.7. Regulations
24.1.8. Regulatory Bodies
24.1.9. Major Associations
24.1.10. Taxes Levied
24.1.11. Corporate Tax Structure
24.1.12. Investments
24.1.13. Major Companies
24.2. South America Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
24.3. South America Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
24.4. South America Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
24.5. South America Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
24.6. South America Anti-Asthmatics and COPD Drugs Market: Country Analysis
24.7. Brazil Anti-Asthmatics and COPD Drugs Market
24.8. Brazil Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
24.9. Brazil Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
24.10. Brazil Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
24.11. Brazil Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
25. Middle East Anti-Asthmatics and COPD Drugs Market
25.1. Middle East Anti-Asthmatics and COPD Drugs Market Overview
25.1.1. Region Information
25.1.2. Market Information
25.1.3. COVID-19 Impact
25.1.4. Background Information
25.1.5. New Drug Trials and Approvals
25.1.6. Government Initiatives
25.1.7. Regulations
25.1.8. Regulatory Bodies
25.1.9. Major Associations
25.1.10. Taxes Levied
25.1.11. Corporate Tax
25.1.12. Major Companies
25.2. Middle East Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
25.3. Middle East Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
25.4. Middle East Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
25.5. Middle East Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
26. Africa Anti-Asthmatics and COPD Drugs Market
26.1. Africa Anti-Asthmatics and COPD Drugs Market Overview
26.1.1. Region Information
26.1.2. Market Information
26.1.3. COVID-19 Impact
26.1.4. Background Information
26.1.5. Government Initiatives
26.1.6. Regulations
26.1.7. Regulatory Bodies
26.1.8. Major Associations
26.1.9. Taxes Levied
26.1.10. Corporate Tax Structure
26.1.11. Investments
26.1.12. Major Companies
26.2. Africa Anti-Asthmatics and COPD Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
26.3. Africa Anti-Asthmatics and COPD Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
26.4. Africa Anti-Asthmatics and COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
26.5. Africa Anti-Asthmatics and COPD Drugs Market, Segmentation By End Users, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
27. Global Anti-Asthmatics and COPD Drugs Market Competitive Landscape
27.1. Company Profiles
27.2. GlaxoSmithKline plc.
27.2.1. Company Overview
27.2.2. Products and Services
27.2.3. Business Strategy
27.2.4. Financial Overview
27.3. AstraZeneca plc.
27.3.1. Company Overview
27.3.2. Products and Services
27.3.3. Business Strategy
27.3.4. Financial Overview
27.4. Boehringer-Ingelheim GmbH
27.4.1. Company Overview
27.4.2. Products and Services
27.4.3. Business Strategy
27.4.4. Financial Overview
27.5. F. Hoffmann-La Roche Ltd
27.5.1. Company Overview
27.5.2. Products and Services
27.5.3. Business Strategy
27.5.4. Financial Overview
27.6. Novartis AG
27.6.1. Company Overview
27.6.2. Products and Services
27.6.3. Business Strategy
27.6.4. Financial Overview
28. Key Mergers and Acquisitions In The Anti-Asthmatics and COPD Drugs Market
28.1. AstraZeneca Gets US Clearance For Proposed Alexion Acquisition
28.2. Roche Acquired Inflazome
28.3. AptarGroup, Inc. Acquired Nanopharm Ltd and Gateway Analytical
28.4. ResMed Acquired Propeller Health
28.5. Circassia Acquired AstraZeneca’s COPD Treatment Tudorza
28.6. RecipharmAB Acquired Sanofi’s Inhalation Contract Manufacturing Business
28.7. Mast Therapeutics, Inc. Merged With Savara Inc.
28.8. Mylan N.V. Acquired Majority Stake In Meda AB
28.9. Vectura Group Merged With Skyepharma
28.10. Recordati Acquired Italchimici S.p.A.
28.11. Ruthigen, Inc. Merged With Pulmatrix, Inc.
29. Market Background: Respiratory Diseases Drugs Market
29.1. Respiratory Diseases Drugs Market Characteristics
29.1.1. Market Definition
29.1.2. Segmentation By Type
29.1.3. Anti-Asthmatics and COPD Drugs
29.1.4. Cough and Cold Preparations
29.2. Global Respiratory Diseases Drugs Market, Segmentation By Type, 2015 - 2025, Value ($ Billion)
29.3. Global Respiratory Diseases Drugs Market, 2020, By Region, Value ($ Billion)
29.4. Global Respiratory Diseases Drugs Market, 2015 - 2025, Historic and Forecast, By Region
30. Anti-Asthmatics and COPD Drugs Market Opportunities and Strategies
30.1. Global Anti-Asthmatics and COPD Drugs Market In 2025 - Countries Offering Most New Opportunities
30.2. Global Anti-Asthmatics and COPD Drugs Market In 2025 - Segments Offering Most New Opportunities
30.3. Global Anti-Asthmatics and COPD Drugs Market In 2025 - Growth Strategies
30.3.1. Market Trend Based Strategies
30.3.2. Competitor Strategies
31. Global Anti-Asthmatics and COPD Drugs Market Recommendations
31.1. Conclusions
31.2. Recommendations
31.2.1. Product
31.2.2. Place
31.2.3. Price
31.2.4. Promotion
31.2.5. People
32. Appendix
32.1. Market Data Sources
32.2. Research Methodology
32.3. Currencies
32.4. Research Inquiries
32.5. About the Publisher
33. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca plc
  • Boehringer-Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
This report describes and explains the global anti-asthmatics and COPD drugs market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.

The global anti-asthmatics and COPD drugs market reached a value of nearly $75,376.4 million in 2020, having increased at a compound annual growth rate (CAGR) of 12.7% since 2015. The market is expected to grow from $75,376.4 million in 2020 to $86,436.2 million in 2025 at a rate of 2.8%. The market is then expected to grow at a CAGR of 5.8% from 2025 and reach $114,413.5 million in 2030.

Growth factors in the historic period include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, rise in healthcare expenditure. The market was restrained by expiration of patents, political uncertainties.

Going forward increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, increasing consumption of fats will drive the growth in the anti-asthmatics and COPD drugs market. Factors that could hinder the growth of the market in the future include side effects associated with respiratory drugs, reduction in free trade, stringent regulations.

The anti-asthmatics and COPD drugs market is segmented by type of drug class into combination drugs, bronchodilators, monoclonal antibodies, and anti-inflammatory drugs. The combination drugs market was the largest segment of the anti-asthmatics and COPD drugs market segmented by drug class, accounting for 37.4% of the total in 2020. Going forward, the monoclonal antibodies market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by drug class, at a CAGR of 6.3% during 2020-2025.

The anti-asthmatics and COPD drugs market is also segmented by type of end user into asthma patients, and COPD patients. The asthma patients end user market was the largest segment of the anti-asthmatics and COPD drugs market segmented by end user, accounting for 61.6% of the total in 2020. Going forward, the COPD patients end user market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by end user, at a CAGR of 3.1% during 2020-2025.

The anti-asthmatics and COPD drugs market is also segmented by distribution channel into general pharmacies, hospital pharmacies, and online retailers. The general pharmacies distribution channel market was the largest segment of the anti-asthmatics and COPD drugs market segmented by distribution channel, accounting for 65.3% of the total in 2020. Going forward, the online retailers distribution channel market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by distribution channel, at a CAGR of 8.0% during 2020-2025.

The anti-asthmatics and COPD drugs market is also segmented by age group into below 5 years, 5 to 14 years, 15-69 years, and 70+ years. The 15-69 Years age group was the largest segment of the anti-asthmatics and COPD drugs market by age group, accounting for $37,950.2 million or 50.3% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by therapy into preventive, and curative. The preventive was the largest segment of the anti-asthmatics and COPD drugs market by therapy, accounting for $40,897.4 million or 54.3% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by route of administration into inhaled, intravenous and subcutaneous, and oral. The inhaled route of administration was the largest segment of the anti-asthmatics and COPD drugs market by route of administration, accounting for $55,104.4 million or 73.1% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by prescription into prescription, and OTC. The prescription was the largest segment of the anti-asthmatics and COPD drugs market by prescription, accounting for $70,421.1 million or 93.4% of the total market in 2020.

The anti-asthmatics and COPD drugs market is also segmented by drug type into branded, and generics. The branded was the largest segment of the anti-asthmatics and COPD drugs market by drug type, accounting for $72,029.6 million or 95.6% of the total market in 2019.

North America was the largest region in the anti-asthmatics and COPD drugs market, accounting for 47.1% of the total in 2020. It was followed by the Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the anti-asthmatics and COPD drugs market will be Asia-Pacific and Middle East where growth will be at CAGRs of 6.6% and 4.1% respectively during 2020-2025. These will be followed by Africa and North America, where the markets are expected to register CAGRs of 2.9% and 1.8% respectively during 2020-2025.

The unprecedented outbreak of coronavirus has caused a surge in demand for essential pharmaceutical drugs, some bronchodilators, and medical devices including anti-asthmatics and COPD drugs. With governments across the world advising people to stay indoors and practice social distancing, to reduce the spread of the pandemic, individuals are hoarding these medications. This has created a sudden rise in demand for anti-asthmatics and COPD drugs. Anti-asthmatics and COPD drug companies should closely monitor the situation and increase supply of essential medicines and other medical devices for 3 to 6 months. Additionally, some anti-asthmatics and COPD drugs such as albuterol are being used in the treatment of COVID-19. In the wake of the pandemic, companies should focus on modifying their supply chain activities to maximize the output to keep up with the rising demand for these drugs.

The anti-asthmatics and COPD drugs market is slightly consolidated, with a small number of large players. The top ten competitors in the market made up to 33.96% of the total market in 2020. Major players in the market include GlaxoSmithKline plc., AstraZeneca plc., Boehringer-Ingelheim GmbH, F. Hoffmann-La Roche Ltd and Novartis AG.

The top growth potential in the anti-asthmatics and COPD drugs market by drug class will arise in monoclonal antibodies market, which will gain $5,055.64 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by end user will arise in the asthma patients market, which will gain $6,249.5 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by distribution channel will arise in general pharmacies market, which will gain $4,863.6 million of global annual sales by 2025. The anti-asthmatics and COPD drugs market size will gain the most in the China’s anti-asthmatics and COPD drugs market at $4,273.5 million.

Market-trend-based strategies for the anti-asthmatics and COPD drugs include companies in the anti-asthmatics and COPD drugs market should invest in developing probiotic drugs for asthma to offer a full range of available treatments, developing anti-IL-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustain their position among intense competition in the market, invest more in developing bioelectric medicines to improve asthma care, focus on increasing the number of collaborations to expand their business portfolio, explore opportunities in personalized medicine to counter the intense competition and provide customized treatment to individuals, invest in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, focus efforts on investing in generic drugs to counter the intense competition, developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics.

Player-adopted strategies in the anti-asthmatics and COPD drugs industry include GlaxoSmithKline’s growth strategy aims at investing more in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers, and consumers. Improving GSK’s pipeline of new medicines remains the first priority of the investment. AstraZeneca plc’s growth strategy aims at strengthening its anti-asthmatics and COPD drugs business through the expansion of its product portfolio. Boehringer Ingelheim’s growth strategy aims at expanding its anti-asthmatic drugs business through strategic investments focusing on expansion of its manufacturing operations. F. Hoffmann-La Roche Ltd.’s growth strategy aims at strengthening its position in the anti-asthmatics and COPD drug market by focusing on innovation in existing anti-asthmatics and COPD drugs. Novartis AG’s growth strategy aims at strengthening its position in the anti-asthmatics and COPD drugs market by focusing on the new drug development and continuous innovation.

To take advantage of the opportunities, the publisher recommends the anti-asthmatics and COPD drugs companies to focus on invest in probiotic drugs, focus on bioelectric medicines, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, premium pricing for branded drugs, companies should focus on increasing awareness on asthma and COPD, leveraging medical advice that asthmatics should ensure they consistently stay up to date with preventative medication to protect against COVID-19, target geriatric populations
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Boehringer-Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown

Loading
LOADING...